You can buy or sell Sunesis and other stocks, options, ETFs, and crypto commission-free!
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Read More The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Research And Development
Seeking AlphaMay 8
Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q1 20189 Results - Earnings Call Transcript
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scientific Officer Deepali Suri - Vice President, Clinical Operations Conference Call Participants Marc Frahm - Cowen and Company Hartaj Singh - Oppenheimer Operator Good afternoon, ladies and gentlemen and welcome to the Q1 201...
Yahoo FinanceMay 8
Sunesis: 1Q Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Wednesday reported a loss of $5.9 million in its first quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 10 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share. In the final minutes of trading on Wednesday, the company's shares hit $1.45. A year ago, they were tradi...
Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights
Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2019. Loss from operations for the three months ended March 31, 2019 was $5.7 million. As of March 31, 2019, cash and cash equivalents totaled $24.8 million. "We continue our focus on the execution of th...
Expected Aug 6, After Hours